Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2014-11-10 Interim / Quarterly Rep…
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2014
2014-11-10 English
FORM 4 SUBMISSION
Director's Dealing
2014-11-04 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from MannKind Corporation to the SEC responding to comments on their previously filed Form 10-K for the fiscal year ended December 31, 2013. It discusses detailed accounting treatments and judgments related to specific financial statement notes, specifically about Milestone Rights and their classification under US GAAP. The letter references the Form 10-K but does not itself contain the full annual report or financial statements. It is a correspondence related to the 10-K filing, providing clarifications and responses to SEC staff comments. The document length is about 13,000 characters, which is substantial but the content is clearly a comment response letter rather than the full annual report. According to the rules, such comment letters and responses to SEC staff questions are classified as Regulatory Filings (RNS), since they do not constitute the full annual report but are regulatory correspondence related to it.
2014-11-04 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated November 3, 2014, reporting financial results for the quarter ended September 30, 2014. It specifically mentions that the press release announcing the quarterly financial results is attached as Exhibit 99.1. The document itself is a current report and does not contain detailed financial statements or substantive financial data but rather references the press release. According to the classification rules, an 8-K filing announcing quarterly financial results corresponds to an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights only, not a full interim report. The document length is 3323 characters, which is short and consistent with an earnings release announcement rather than a full interim report. Therefore, the appropriate classification is Earnings Release (ER).
2014-11-03 English
Regulatory Filings 2014
Regulatory Filings
2014-10-23 English
FORM 4 SUBMISSION
Director's Dealing
2014-10-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.